PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis

被引:458
作者
Jiang, Bing-Hua [1 ,2 ,3 ]
Liu, Ling-Zhi [1 ,2 ]
机构
[1] W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA
[2] W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA
[3] Nanjing Med Univ, Dept Pathol, Ctr Canc, Nanjing 210029, Jiangsu, Peoples R China
来源
ADVANCES IN CANCER RESEARCH, VOL 102 | 2009年 / 102卷
关键词
ENDOTHELIAL-GROWTH-FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; PHASE-II TRIAL; NF-KAPPA-B; HYPOXIA-INDUCIBLE FACTOR; ADVANCED SOLID TUMORS; RENAL-CELL CARCINOMA; RECURRENT MALIGNANT GLIOMA; SMOOTH-MUSCLE-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE/MAMMALIAN TARGET;
D O I
10.1016/S0065-230X(09)02002-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Phosphatidylinositol 3-kinase (PI3K) and phosphatase and tensin homolog deleted on chromosome 10 (PTEN) signaling pathway play an important role in multiple cellular functions such as cell metabolism, proliferation, cell-cycle progression, and survival. PI3K is activated by growth factors and angiogenesis inducers such is vascular endothelial growth factor (VEGF) and angiopoietins. The amplification and Mutations of PI3K and the loss of the tumor suppressor PTEN are common in various kinds of human solid tumors. The genetic alterations of upstream and downstream of PI3K signaling molecules such as receptor tyrosine kinases and AKT, respectively, are also frequently altered in human cancer. PI3K signaling regulates tumor growth and angiogenesis by activating AKT and other targets, and by inducing HIF-1 and VEGF expression. Angiogenesis is required for tumor growth and metastasis. In this review, we highlight the recent studies on the roles and mechanisms of PI3K and PTEN in regulating tumorigenesis and angiogenesis, and the roles of the downstream targets of PI3K for transmitting the signals. We also discuss the crosstalk of these signaling molecules and Cellular events during tumor growth, metastasis, and tumor angiogenesis. Finally, we Summarize the potential applications of PI3K, AKT, and mTOR inhibitors and their Outcome in clinical trials for cancer treatment. (C) 2009 Elsevier Inc.
引用
收藏
页码:19 / 65
页数:47
相关论文
共 278 条
[1]   Akt1/protein kinase Bα is critical for ischemic and VEGF-mediated angiogenesis [J].
Ackah, E ;
Yu, J ;
Zoellner, S ;
Iwakiri, Y ;
Skurk, C ;
Shibata, R ;
Ouchi, N ;
Easton, RM ;
Galasso, G ;
Birnbaum, MJ ;
Walsh, K ;
Sessa, WC .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (08) :2119-2127
[2]   The AKT/IκB kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-κB and β-catenin [J].
Agarwal, A ;
Das, K ;
Lerner, N ;
Sathe, S ;
Cicek, M ;
Casey, G ;
Sizemore, N .
ONCOGENE, 2005, 24 (06) :1021-1031
[3]   Role of nuclear factor-κB in melanoma [J].
Amiri, KI ;
Richmond, A .
CANCER AND METASTASIS REVIEWS, 2005, 24 (02) :301-313
[4]   Phosphatidylinositol 3-kinase in breast cancer: Where from here? [J].
Angelo, Paradiso ;
Anita, Mangia ;
Amalia, Azzariti ;
Stefania, Tommasi .
CLINICAL CANCER RESEARCH, 2007, 13 (20) :5988-5990
[5]   Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors [J].
Arcaro, A ;
Zvelebil, MJ ;
Wallasch, C ;
Ullrich, A ;
Waterfield, MD ;
Domin, J .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (11) :3817-3830
[6]   A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer [J].
Argiris, Athanassios ;
Cohen, Ezra ;
Karrison, Theodore ;
Esparaz, Benjamin ;
Mauer, Ann ;
Ansari, Rafat ;
Wong, Stuart ;
Lu, Yi ;
Pins, Michael ;
Dancey, Janet ;
Vokes, Everett .
CANCER BIOLOGY & THERAPY, 2006, 5 (07) :766-770
[7]   Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].
Atkins, MB ;
Hidalgo, M ;
Stadler, WM ;
Logan, TF ;
Dutcher, JP ;
Hudes, GR ;
Park, Y ;
Lion, SH ;
Marshall, B ;
Boni, JP ;
Dukart, G ;
Sherman, ML .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918
[8]   Role of PIGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 [J].
Autiero, M ;
Waltenberger, J ;
Communi, D ;
Kranz, A ;
Moons, L ;
Lambrechts, D ;
Kroll, J ;
Plaisance, S ;
De Mol, M ;
Bono, F ;
Kliche, S ;
Fellbrich, G ;
Ballmer-Hofer, K ;
Maglione, D ;
Mayr-Beyrle, U ;
Dewerchin, M ;
Dombrowski, S ;
Stanimirovic, D ;
Van Hummelen, P ;
Dehio, C ;
Hicklin, DJ ;
Persico, G ;
Herbert, JM ;
Communi, D ;
Shibuya, M ;
Collen, D ;
Conway, EM ;
Carmeliet, P .
NATURE MEDICINE, 2003, 9 (07) :936-943
[9]   The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer:: Results of a phase I study with pharmacokinetics [J].
Awada, Ahmad ;
Cardoso, Fatima ;
Fontaine, Christel ;
Dirix, Luc ;
De Greve, Jacques ;
Sotiriou, Christos ;
Steinseifer, Jutta ;
Wouters, Carine ;
Tanaka, Chiaki ;
Zoellner, Ulrike ;
Tang, Pui ;
Piccart, Martine .
EUROPEAN JOURNAL OF CANCER, 2008, 44 (01) :84-91
[10]   Angiogenic actions of angiopoietin-1 require endothelium-derived nitric oxide [J].
Babaei, S ;
Teichert-Kuliszewska, K ;
Zhang, QW ;
Jones, N ;
Dumont, DJ ;
Stewart, DJ .
AMERICAN JOURNAL OF PATHOLOGY, 2003, 162 (06) :1927-1936